ArticleAnnals of medicine and surgery (2012)2026
MRI O-RADS: redefining diagnostic accuracy in characterization of ovarian lesions with histopathology as the benchmark.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- O-RADS for assessment of adnexal lesions: current status, challenges and future directions.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adnexal lesions are a common gynecological concern requiring accurate distinction between benign and malignant types for optimal clinical management. The Ovarian-Adnexal Reporting and Data System for magnetic resonance imaging (MRI) (O-RADS MRI) aim to standardize risk assessment and enhance diagnostic precision. Objective: To evaluate the diagnostic accuracy of MRI using O-RADS MRI criteria, with histopathology as the gold standard. Methods: This descriptive cross-sectional study was conducted from January to June 2025 at the Dow Institute of Radiology, Dow University of Health Sciences (DUHS), Karachi, Pakistan. Women aged 18-65 years undergoing contrast-enhanced MRI for ultrasound-detected ovarian lesions, with available histopathology, were included. Patients with prior surgery, chemotherapy, radiotherapy, pregnancy, lactation, other malignancies, or inconclusive histopathology were excluded. O-RADS MRI scores were assigned by an experienced radiologist. Diagnostic metrics including sensitivity, specificity, predictive values, likelihood ratios, overall accuracy, and area under the curve (AUC) were calculated. Results: Among 145 patients (62.76% premenopausal, 37.24% postmenopausal), O-RADS categories 3 (32.41%) and 4 (31.03%) were most frequent. Benign lesions predominated in premenopausal women (60.44%), while malignant lesions were more common in postmenopausal women (66.67%). Common benign lesions included hemorrhagic cysts (14.48%), endometriomas (9.66%), and serous cystadenomas (6.90%), while serous cystadenocarcinoma (14.48%) was the most frequent malignancy. Using O-RADS ≥4 as the threshold for malignancy, sensitivity was 93.10%, specificity 79.31%, positive predictive value 75.00%, negative predictive value 94.52%, overall accuracy 84.83%, and AUC 0.921. Redefining O-RADS categories 3-5 as positive markedly reduced diagnostic accuracy to 56.42% and sensitivity to 66.67. Conclusion: The O-RADS MRI scoring system demonstrated excellent diagnostic accuracy in distinguishing benign from malignant ovarian lesions, supporting its role in clinical decision-making and risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.